Biocon Biologics launches Yesintek biosimilar to Stelara in US: Our Bureau, Bengaluru Tuesday, February 25, 2025, 15:40 Hrs [IST] Biocon Biologics has announced that Yesintek (ust ...

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

The company, along with its subsidiary NTPC Green Energy, has entered into multiple MoUs with the Madhya Pradesh government ...

As per provisional closing data, the barometer index, the S&P BSE Sensex, advanced 147.71 points or 0.20% to 74,602.12. The Nifty 50 index fell 5.80 points or 0.03% to 22,547.55.

IST, the barometer index, the S&P BSE Sensex, advanced 183.55 points or 0.25% to 74,645.46. The Nifty 50 index added 19.75 points or 0.09% to 22,573.10.

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's ...

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private ...

Revolt Motors, India’s No.1 electric motorcycle brand, has launched the all-new RV BlazeX - a high-performance, smart, and ...